Effect of febuxostat on adverse events and mortality in gout in Taiwan: An interrupted time series analysis

Abstract

AbstractObjectivesTo evaluate the influence of febuxostat on adverse events and mortality in gout.MethodsWe retrospectively enrolled patients with newly diagnosed gout and prescribed urate‐lowering therapy between 2006 and 2017 from the Taiwan National Health Insurance Database. These patients were divided into 2 groups: with and without comorbidities (n = 294 847 and 194 539). An interrupted time series analysis with adjustments for demographics, comorbidities, and comedication by propensity score‐based stabilized weights was used to compare the trend of adverse events and mortality before vs after febuxostat was introduced in 2012.ResultsThe proportion of febuxostat use gradually increased from 0% in 2012 to 30% in those with comorbidities and 10% in those without comorbidities in 2017. Allopurinol use decreased from 30% in 2012 to 10% in 2017. The slope of the 1‐year incidence rate of Stevens–Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) (per 10 000 patients) significantly reduced after 2012 in those with and without comorbidities (−0.375 per quarter, P = .015 and −.253 per quarter, P = .049). The slope of the 3‐year incidence rate of acute myocardial infarction (AMI) (per 1000 patients), percutaneous coronary intervention (PCI) (per 1000 patients), and all‐cause mortality (per 100 patients) significantly increased after 2012 in those with comorbidities (+0.207 per quarter, P = .013; +.389 per quarter, P = .002; +.103 per quarter, P = .001).ConclusionsFebuxostat may reduce SJS and TEN in all gout patients but increase AMI, PCI, and all‐cause mortality in gout patients with comorbidities.